Literature DB >> 18573275

Modafinil decreases food intake in humans subjected to simulated shift work.

Gydmer A Perez1, Margaret Haney, Richard W Foltin, Carl L Hart.   

Abstract

In a limited number of studies modafinil has been shown to decrease food intake by laboratory animals and humans. The present study represents a secondary data analysis, in which the effects of modafinil on several measures of food intake were determined in humans living in a residential laboratory during simulated shift work. During this 23-day study, a wide selection of food items and beverages were freely available. During this double-blind, within-participant study, volunteers (N = 11) received oral modafinil dose (0, 200, or 400 mg) 1 h after waking for three consecutive days under two shift conditions: day shift and night shift. Shifts alternated three times during the study, and shift conditions were separated by an "off" day. Modafinil (200, 400 mg) dose-dependently decreased total caloric intake by approximately 18% and approximately 38%, respectively, regardless of shift condition, without selectively altering the proportion of total calories derived from carbohydrate, fat and protein. Ratings of "Hungry" were also significantly decreased by both active doses, but only immediately before the lunch break period. In addition, tolerance to the anorexic effects of modafinil was not apparent, as these effects remained stable across the three days of modafinil dosing. These findings show that modafinil produced clear reductions in food intake and suggest that future prospective studies should examine the drug in obese participants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573275      PMCID: PMC5858899          DOI: 10.1016/j.pbb.2008.05.018

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  34 in total

1.  Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression.

Authors:  Luca Ferraro; Kjell Fuxe; Sergio Tanganelli; Maria Cristina Tomasini; Francis A Rambert; Tiziana Antonelli
Journal:  J Neurosci Res       Date:  2002-04-01       Impact factor: 4.164

2.  Modafinil attenuates disruptions in cognitive performance during simulated night-shift work.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Erik Gunderson; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

3.  Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.

Authors:  Joseph Biederman; James M Swanson; Sharon B Wigal; Christopher J Kratochvil; Samuel W Boellner; Craig Q Earl; John Jiang; L Greenhill
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

4.  Modafinil binds to the dopamine uptake carrier site with low affinity.

Authors:  E Mignot; S Nishino; C Guilleminault; W C Dement
Journal:  Sleep       Date:  1994-08       Impact factor: 5.849

5.  Acute behavioral and physiological effects of modafinil in drug abusers.

Authors:  C R Rush; T H Kelly; L R Hays; R W Baker; A F Wooten
Journal:  Behav Pharmacol       Date:  2002-03       Impact factor: 2.293

6.  Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil.

Authors:  J P Wisor; K S Eriksson
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

7.  Zolpidem-related effects on performance and mood during simulated night-shift work.

Authors:  Carl L Hart; Amie S Ward; Margaret Haney; Richard W Foltin
Journal:  Exp Clin Psychopharmacol       Date:  2003-11       Impact factor: 3.157

8.  Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work.

Authors:  Carl L Hart; Amie S Ward; Margaret Haney; Jennifer Nasser; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

9.  Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity.

Authors:  Angela P Makris; Craig R Rush; Robert C Frederich; Thomas H Kelly
Journal:  Appetite       Date:  2004-04       Impact factor: 3.868

10.  Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study.

Authors:  Max Hirshkowitz; Jed Black
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more
  5 in total

1.  Narcolepsy with cataplexy associated with nocturnal compulsive behaviors: a case-control study.

Authors:  Vincenzo Palaia; Francesca Poli; Fabio Pizza; Elena Antelmi; Christian Franceschini; Keivan Kaveh Moghadam; Frederica Provini; Uberto Pagotto; Pasquale Montagna; Carlos H Schenck; Emmanuel Mignot; Giuseppe Plazzi
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

2.  A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Matthew G Kirkpatrick; Erik W Gunderson; Audrey Y Perez; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2011-06-30       Impact factor: 4.530

3.  Low striatal dopamine receptor availability linked to caloric intake during abstinence from chronic methamphetamine abuse.

Authors:  T Zorick; B Lee; M A Mandelkern; T Fong; C Robertson; D G Ghahremani; A K Brown; B Sumerel; E D London
Journal:  Mol Psychiatry       Date:  2011-10-25       Impact factor: 15.992

4.  Depression-like deficits in rats improved by subchronic modafinil.

Authors:  Ralf Regenthal; Holger Koch; Christian Köhler; Rainer Preiss; Ute Krügel
Journal:  Psychopharmacology (Berl)       Date:  2009-03-03       Impact factor: 4.530

5.  Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.

Authors:  Stéphane Krief; Isabelle Berrebi-Bertrand; Isabelle Nagmar; Martin Giret; Simon Belliard; David Perrin; Marilyne Uguen; Philippe Robert; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Olivier Finance; Xavier Ligneau
Journal:  Pharmacol Res Perspect       Date:  2021-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.